Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16922165 | 0.88 | CNR2 (0.72) | CNR2NR1I2ADORA3CNR1SLC6A3 | |
| SCHEMBL15558108 | 0.88 | CNR2 (0.72) | CNR2NR1I2ADORA3CNR1SLC6A3 | |
| SCHEMBL31545381 | 0.88 | CNR2 (0.72) | CNR2NR1I2ADORA3CNR1SLC6A3 | |
| SCHEMBL11455743 | 0.88 | CNR2 (0.72) | CNR2NR1I2ADORA3CNR1SLC6A3 | |
| SCHEMBL7755404 | 0.88 | CNR2 (0.72) | CNR2NR1I2ADORA3CNR1SLC6A3 | |
| SCHEMBL11541884 | 0.88 | CNR2 (0.72) | CNR2NR1I2ADORA3CNR1SLC6A3 | |
| SCHEMBL17686850 | 0.88 | CNR2 (0.71) | CNR2NR1I2ADORA3CNR1SLC6A3 | |
| SCHEMBL11444967 | 0.87 | CNR2 (0.71) | CNR2NR1I2ADORA3CNR1SLC6A3 | |
| SCHEMBL11787625 | 0.87 | CNR2 (0.71) | CNR2NR1I2ADORA3CNR1SLC6A3 | |
| SCHEMBL11612711 | 0.87 | CNR2 (0.71) | CNR2NR1I2ADORA3CNR1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9347961-B2 | Test kit for the quantitative determination of narcotic drugs | CHIRON AS (NO) | 2016-05-24 | — | — | US | disclosed |
| US-9155797-B2 | Oligomer-cannabinoid conjugates | NEKTAR THERAPEUTICS (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150204893-A1 | TEST KIT FOR THE QUANTITATIVE DETERMINATION OF NARCOTIC DRUGS | CHIRON AS (NO) | 2015-07-23 | — | — | US | disclosed |
| US-20140329895-A1 | OLIGOMER-CANNABINOID CONJUGATES | NEKTAR THERAPEUTICS | 2014-11-06 | — | — | US | disclosed |
| US-8829043-B2 | Oligome-cannabinoid conjugates | NEKTAR THERAPEUTICS (US) | 2014-09-09 | — | — | US | disclosed |
| US-20120022063-A1 | Oligomer-Cannabinoid Conjugates | NEKTAR THERAPEUTICS (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329895-A1 | OLIGOMER-CANNABINOID CONJUGATES | CNR2, CNR1, OPRL1 | CNR2 1/4885NR1I2 1714/4885ADORA3 461/4885 |
| US-20120022063-A1 | Oligomer-Cannabinoid Conjugates | CNR2, CNR1, OPRL1 | CNR2 1/4885NR1I2 1714/4885ADORA3 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.